Optimization of Darunavir Therapy and Dosage Recommendations
Status:
Completed
Trial end date:
2019-06-12
Target enrollment:
Participant gender:
Summary
This study will assess and characterize the variability observed in the response to darunavir
therapy, an antiretroviral medication used against the Human Immunodeficiency Virus (HIV).
More specifically, it aims to quantify variations in the drug's blood concentrations and
determine the sources of such variability, both genetic and non-genetic. In light of this
information, current dosage guidelines will then be reviewed.
Phase:
Phase 4
Details
Lead Sponsor:
Université Catholique de Louvain
Collaborator:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain